{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:09:20Z","timestamp":1792674560152,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Metabolic heterogeneity (MH) can be measured using 18F-fluorodeoxyglucose (18FDG) positron emission tomography\/computed tomography (PET\/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone\u2013like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline 18FDG-PET\/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001816","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T15:30:58Z","timestamp":1590507058000},"page":"2286-2296","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5382-5167","authenticated-orcid":false,"given":"Hajime","family":"Senjo","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-8975","authenticated-orcid":false,"given":"Kenji","family":"Hirata","sequence":"first","affiliation":[{"name":"Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Izumiyama","sequence":"first","affiliation":[{"name":"Blood Disorders Center, Aiiku Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Minauchi","sequence":"first","affiliation":[{"name":"Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tsukamoto","sequence":"first","affiliation":[{"name":"Department of Radiology, Central CI Clinic, Sapporo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Itoh","sequence":"first","affiliation":[{"name":"Department of Radiology, Keiyukai Sapporo Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-8657","authenticated-orcid":false,"given":"Minoru","family":"Kanaya","sequence":"first","affiliation":[{"name":"Blood Disorders Center, Aiiku Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Mori","sequence":"first","affiliation":[{"name":"Blood Disorders Center, Aiiku Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-244X","authenticated-orcid":false,"given":"Shuichi","family":"Ota","sequence":"first","affiliation":[{"name":"Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-9704","authenticated-orcid":false,"given":"Daigo","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"North Japan Hematology Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"1","key":"2020052611304734700_B1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2020052611304734700_B2","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2020052611304734700_B3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2020052611304734700_B4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1973","article-title":"Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18F-FDG PET\/CT in newly diagnosed patients with diffuse large B-cell lymphoma","volume":"8","author":"Senjo","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"2020052611304734700_B5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and implications of metabolic heterogeneity in cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"2020052611304734700_B6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood"},{"issue":"27","key":"2020052611304734700_B7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020052611304734700_B8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020052611304734700_B9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"2020052611304734700_B10","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020052611304734700_B11","doi-asserted-by":"crossref","first-page":"e105682","DOI":"10.1371\/journal.pone.0105682","article-title":"A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT","volume":"9","author":"Hirata","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"2020052611304734700_B12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-018-4100-6","article-title":"Radiomics analysis of pre-treatment [18F]FDG PET\/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment","volume":"45","author":"van Helden","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2020052611304734700_B13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-011-1845-6","article-title":"Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies","volume":"38","author":"van Velden","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2020052611304734700_B14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2020052611304734700_B15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J Gen Physiol"},{"issue":"1","key":"2020052611304734700_B16","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1038\/s41467-019-11738-0","article-title":"Metabolic landscape of the tumor microenvironment at single cell resolution","volume":"10","author":"Xiao","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2020052611304734700_B17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.23736\/S1824-4785.16.02862-4","article-title":"Clinical value of intratumoral metabolic heterogeneity in [18F]FDG PET\/CT for prediction of recurrence in patients with locally advanced colorectal cancer","volume":"62","author":"Han","year":"2018","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"5","key":"2020052611304734700_B18","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1097\/RLU.0000000000001578","article-title":"Value of intratumoral metabolic heterogeneity and quantitative 18F-FDG PET\/CT parameters to predict prognosis in patients with hpv-positive primary oropharyngeal squamous cell carcinoma","volume":"42","author":"Mena","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2020052611304734700_B19","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/RLU.0000000000001446","article-title":"18F-FDG PET\/CT metabolic tumor volume and intratumoral heterogeneity in pancreatic adenocarcinomas: impact of dual-time point and segmentation methods","volume":"42","author":"Mena","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2020052611304734700_B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejrad.2018.07.028","article-title":"Metabolic tumor heterogeneity analysis by F-18 FDG PET\/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2","volume":"106","author":"Pahk","year":"2018","journal-title":"Eur J Radiol"},{"issue":"9","key":"2020052611304734700_B21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd3504","article-title":"Targeting cancer metabolism: a therapeutic window opens","volume":"10","author":"Vander Heiden","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2020052611304734700_B22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fcell.2019.00004","article-title":"Hypoxia-modified cancer cell metabolism","volume":"7","author":"Al Tameemi","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2020052611304734700_B23","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.1219555110","article-title":"Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma","volume":"110","author":"Guillaumond","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2020052611304734700_B24","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"issue":"12","key":"2020052611304734700_B25","first-page":"3930","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Sonveaux","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"2020052611304734700_B26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2214\/AJR.11.7336","article-title":"Nasopharyngeal carcinoma: investigation of intratumoral heterogeneity with FDG PET\/CT","volume":"199","author":"Huang","year":"2012","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"2020052611304734700_B27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv"},{"issue":"6769","key":"2020052611304734700_B28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"10","key":"2020052611304734700_B29","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1349-7006.2009.01268.x","article-title":"Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era","volume":"100","author":"Seki","year":"2009","journal-title":"Cancer Sci"},{"issue":"7","key":"2020052611304734700_B30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","article-title":"CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab","volume":"22","author":"Miyazaki","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"2020052611304734700_B31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2245","article-title":"The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients","volume":"35","author":"Okamoto","year":"2017","journal-title":"Hematol Oncol"},{"issue":"28","key":"2020052611304734700_B32","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020052611304734700_B33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2020052611304734700_B34","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2286\/1732392\/advancesadv2020001816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2286\/1732392\/advancesadv2020001816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T15:31:21Z","timestamp":1590507081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/10\/2286\/456146\/High-metabolic-heterogeneity-on-baseline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001816","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]}}}